Evidence map›Paper›PMID 32253554›Full record

ArticleInvestigational new drugs2020

Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.

Nataliya V Uboha, Sam J Lubner, Noelle K LoConte, Daniel L Mulkerin, Jens C Eickhoff, Dustin A Deming

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Chemotherapy in NEN: still has a role?Reviews in endocrine & metabolic disorders · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nataliya V UbohaCarbone Cancer Center, University of Wisconsin, Madison, WI, USA. nvuboha@medicine.wisc.edu.
Sam J LubnerCarbone Cancer Center, University of Wisconsin, Madison, WI, USA.
Noelle K LoConteCarbone Cancer Center, University of Wisconsin, Madison, WI, USA.
Daniel L MulkerinCarbone Cancer Center, University of Wisconsin, Madison, WI, USA.
Jens C EickhoffCarbone Cancer Center, University of Wisconsin, Madison, WI, USA.
Dustin A DemingCarbone Cancer Center, University of Wisconsin, Madison, WI, USA.
University of Wisconsin–Madison · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Nihal Ahmad · 1985 to 2026
$142.6M
School of Medicine and Public Health, University of Wisconsin-Madison Grant P30 CA014520
6 · The paper itself

Abstract

Neuroendocrine tumors (NETs) are understudied and have limited systemic treatment options. Prior studies for patients with advanced NETs have demonstrated promising results when antimetabolite agents, including fluoropyrimidines, were combined with temozolomide TMZ. TAS-102 (trifluridine/tipiracil) is an antineoplastic agent that is non-cross resistant with 5-fluorouracil and capecitabine and that has a different toxicity profile. This study evaluated the safety of TAS-102 in combination with TMZ in patients in neuroendocrine tumors. Escalating doses of TMZ (100, 150 and 200 mg/m

Indexed as

AdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDrug CombinationsFemaleHematologic DiseasesHumansMaleMaximum Tolerated DoseMiddle AgedNeuroendocrine TumorsPyrrolidinesTemozolomideThymineTreatment OutcomeAntineoplastic AgentsDrug CombinationsPyrrolidinesTemozolomideThymineTrifluridinetrifluridine tipiracil drug combinationNeuroendocrine tumorPhase 1TAS-102Temozolomide

Identifiers

PMID32253554
OpenAlexW3014148824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.